Clinical Trials at NIH: Clinical Research: Search for Clinical Trials at NIH

The National Cancer Institute (NCI) conducts more than 150 cancer clinical trials at the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland. Cancer clinical trials that take place at the NIH Clinical Center are open to patients with cancer, regardless of where they live in the United States.

Go to Search Page

There are 30 clinical trials at NIH that match your search criteria

Cancer by type: Solid Tumor

Trial and Protocol Number Solid Tumor	Principal Investigator	Referral Contact
Phase I/II
Phase I/II Study of Metastatic Cancer that Expresses HER-2 Using Lymphodepleting Conditioning Followed by Infusion of Anti-HER-2 Gene Engineered Lymphocytes NCI-09-C-0041	Steven A. Rosenberg 1-866-820-4505 (Toll Free)	Linda Williams 1-866-820-4505 (Toll Free) ncisbirc@mail.nih.gov

Trial and Protocol Number Solid Tumor (Adult)	Principal Investigator	Referral Contact
Phase II
Phase II Study of Metastatic Cancer that Expresses Carcinoembryonic Antigen (CEA) Using Lymphodepleting Conditioning Followed by Infusion of Anti-CEA TCR-Gene Engineered Lymphocytes NCI-09-C-0047	Steven A. Rosenberg 1-866-820-4505 (Toll Free)	Linda Williams 1-866-820-4505 (Toll Free) ncisbirc@mail.nih.gov
Phase II Study of Metastatic Cancer That Overexpresses p53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-p53 TCR-Gene Engineered Lymphocytes and Dendritic Cell Vaccination NCI-08-C-0155	Steven A. Rosenberg 1-866-820-4505 (Toll Free)	Linda Williams 1-866-820-4505 (Toll Free) ncisbirc@mail.nih.gov
Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 TCR-Gene Engineered Lymphocytes NCI-08-C-0121	Steven A. Rosenberg 1-866-820-4505 (Toll Free)	Linda Williams 1-866-820-4505 (Toll Free) ncisbirc@mail.nih.gov
A Phase II Study of Hypofractionated Highly Conformal Radiation With Helical Tomotherapy for Extra-Cranial Oligometastases NCI-07-C-0230	Deborah Citrin 301-496-5457	Sharon L. Smith 301-496-5457 smiths@mail.nih.gov
Phase I
A Phase I Study of ABT-888 in Combination With Metronomic Cyclophosphamide in Adults With Refractory Solid Tumors and Lymphomas NCI-09-C-0048	Shivaani Kummar 301-435-5402	Deborah Allen 301-402-5640 allendeb@mail.nih.gov
A Phase I Study of Dasatinib in Combination With Bevacizumab in Advanced Solid Tumors NCI-09-C-0019	Elise C. Kohn 301-402-2726	Laura D. Otten 301-451-1228 1-866-611-6310 (Toll Free) ottenl@mail.nih.gov
A Phase I and Pharmacokinetic Single-Agent Study of Pazopanib in Adults With Advanced Malignancies and Varying Degrees of Liver Dysfunction NCI-09-C-0003	Shivaani Kummar 301-435-5402	Laura D. Otten 301-451-1228 1-866-611-6310 (Toll Free) ottenl@mail.nih.gov
A Phase I Combination Study of AZD2281 and Cisplatin Plus Gemcitabine in Adults With Solid Tumors NCI-08-C-0128	Giuseppe Giaccone 301-496-4916	Janelle Bingham 301-435-2715 jbingham@mail.nih.gov
Phase I Study of SNX-5422 Mesylate in Adults With Refractory Solid Tumor Malignancies and Lymphomas NCI-08-C-0091	Giuseppe Giaccone 301-496-4916	Janelle Bingham 301-435-2715 jbingham@mail.nih.gov
Phase I Study of Vandetanib (ZD 6474) and Bevacizumab Combination Therapy Evaluating the VEGF and EGF Signal Transduction Pathways in Adults With Solid Tumors and Lymphomas NCI-08-C-0087	Shivaani Kummar 301-435-5402	Deborah Allen 301-402-5640 allendeb@mail.nih.gov
Phase I Trial of Fenretinide (4-HPR, NSC 374551) Lym-X-Sorb^TM (LXS) Oral Powder (4-HPR/LXS Oral Powder) (4-HPR) in Adults With Solid Tumors and Lymphomas NCI-08-C-0030	Anthony J. Murgo 301-496-4291	Janelle Bingham 301-435-2715 jbingham@mail.nih.gov
Phase I and Pharmacokinetic Study of Vorinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction NCI-07-C-0228	Shivaani Kummar 301-435-5402	Janelle Bingham 301-435-2715 jbingham@mail.nih.gov
A Phase I Study of ABT-888 in Combination With Topotecan Hydrochloride in Adults With Refractory Solid Tumors and Lymphomas NCI-07-C-0203	Shivaani Kummar 301-435-5402	Janelle Bingham 301-435-2715 jbingham@mail.nih.gov
A Phase I Study of Batracylin (NSC320846) in Subjects With Solid Tumors and Lymphomas NCI-07-C-0097	Anthony J. Murgo 301-496-4291	Janelle Bingham 301-435-2715 jbingham@mail.nih.gov
A Phase I Trial of Nelfinavir (Viracept^®) in Adults With Solid Tumors NCI-07-C-0047	Phillip A. Dennis 301-496-0929	Hyejeong Root 301-402-0998 roothy@mail.nih.gov
A Phase I Trial of 5-Fluoro-2-Deoxycytidine With Tetrahydrouridine in Advanced Malignancies NCI-06-C-0221	James Doroshow 301-496-4291	Janelle Bingham 301-435-2715 jbingham@mail.nih.gov
A Pilot Trial of Oral Topotecan for the Treatment of Refractory Advanced Solid Neoplasms Expressing HIF-1 Alpha NCI-05-C-0186	Shivaani Kummar 301-435-5402	Janelle Bingham 301-435-2715 jbingham@mail.nih.gov
A Phase I Investigation of IL-12/Pulse IL-2 in Adults With Advanced Solid Tumors NCI-00-C-0121	John E. Janik 301-402-2913	Guinevere Chun 301-451-7868 gchun@mail.nih.gov
Phase 0
A Phase 0 Trial of [111] Indium CHX-A" DTPA Trastuzumab Imaging in Cancer NCI-07-C-0101	Peter Choyke 301-451-4220	Yolanda McKinney 301-443-1718 ymckinney@mail.nih.gov
No Phase
A Pilot Study of Markers of Tumor Burden and Radiation Toxicity in the Blood, Urine, and Stool of Patients Receiving Radiotherapy for Gastrointestinal Malignancies NCI-07-C-0111	Deborah Citrin 301-496-5457	Sharon L. Smith 301-496-5457 smiths@mail.nih.gov
Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease NCI-97-C-0147	W. Marston Linehan 301-496-6353

Trial and Protocol Number Solid Tumor (Childhood)	Principal Investigator	Referral Contact
Phase I
A Phase I Study of VEGF Trap (NSC #724770, IND #100137) in Children With Refractory Solid Tumors (Children’s Oncology Group Study ADVL0714) NCI-08-C-0179	Elizabeth Fox 301-402-6641	Pediatric Oncology 1-877-624-4878 (Toll free)
Multiple Ascending Dose (MAD) Phase I Study of the IGF-1R Antagonist R1507 Administered as an Intravenous Infusion in Children and Adolescents With Advanced Solid Tumors NCI-08-C-0010	Frank Balis 301-496-0085	Pediatric Oncology 1-877-624-4878 (Toll free)
A Phase I Study of Ipilimumab (Anti-CTLA-4) in Children, Adolescents, and Young Adults With Treatment Refractory Cancer NCI-08-C-0007	Crystal Mackall 301-402-5940	Pediatric Oncology 1-877-624-4878 (Toll free)
A Phase I Study of BMS-354825 (Dasatinib) in Children With Recurrent/Refractory Solid Tumors or Imatinib Resistant Ph+ Leukemia (A Cooperative Group Study) NCI-07-C-0166	Elizabeth Fox 301-402-6641	Pediatric Oncology 1-877-624-4878 (Toll free)
A Phase I Trial and Pharmacokinetic Study of Trabectedin (YONDELIS^®, ET-743) in Children and Adolescents With Relapsed or Refractory Solid Tumors NCI-07-C-0054	Elizabeth Fox 301-402-6641	Pediatric Oncology 1-877-624-4878 (Toll free)
Phase I Trial of Monoclonal Antibody HGS-ETR2 (Lexatumumab) in Patients With Refractory Pediatric Solid Tumors NCI-07-C-0040	Crystal Mackall 301-402-5940	Pediatric Oncology 1-877-624-4878 (Toll free)

Trial and Protocol Number Pediatric Cancers	Principal Investigator	Referral Contact
Phase I
A Phase I Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor BAY 43-9006 (Sorafenib) in Children With Refractory Solid Tumors or Refractory Leukemias NCI-06-C-0233	Brigitte Widemann 301-496-7387	Pediatric Oncology 1-877-624-4878 (Toll free)
Phase I Trial of Cediranib (AZ2171), an Orally Bioavailable Antiangiogenic Agent, in Children and Adolescents With Refractory or Recurrent Solid Tumors or Acute Myelogenous Leukemia NCI-06-C-0152	Elizabeth Fox 301-402-6641	Pediatric Oncology 1-877-624-4878 (Toll free)

If there are no studies listed for your specific disease type, please search under:

Solid Tumor (advanced malignancy)